GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells
Biological Chemistry 390 (7): 601-609 Abstract The disialoganglioside GD3 is an oncofetal marker of a variety of human tumors including melanoma and neuroblastoma, playing a key role in tumor progression. GD3 and 9-O-acetyl-GD3 are overexpressed in approximately 50% of invasive ductal breast carcinoma, but no relationship has been established between disialoganglioside expression and breast cancer progression. In order to determine the effect of GD3 expression on breast cancer development, we analyzed the biosynthesis of gangliosides in several breast epithelial cell lines including MDA-MB-231, MCF-7, BT-20, T47-D, and MCF10A, by immunocytochemistry, flow cytometry, and real-time PCR. Our results show that, in comparison to tumors, cultured breast cancer cells express a limited pattern of ......
POSTED 07/01/2009 at 01:20 PM --
|
Protein Linked To Change In Tissue That Surround And Support Breast Tumors
A protein known to be overly active in breast cancer can exist in a form that seems to change the structural composition of mammary tissue, potentially making it more conducive to tumor progression, say researchers. (Source: ScienceDaily Headlines)...
POSTED 07/01/2009 at 01:19 PM --
|
Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians
Conclusions: The results indicate that the VDR poly-A polymorphism is significantly associated with breast cancer risk in north Indians especially with early onset disease. Although, ApaI and TaqI did not show any significant association with the disease when analyzed in isolation, but TaqI might modulate the risk associated with L alleles. Further, understanding the functional role of these variants residing on the VDR haplotype associated with disease susceptibility may suggest novel approaches for breast cancer prevention and therapy. (Source: Cancer Detection and Prevention)...
POSTED 07/01/2009 at 10:01 AM --
|
Adjuvant Radiotherapy Reduces Recurrences With Small Breast Tumors
ORLANDO (EGMN) - The use of adjuvant radiation therapy following mastectomy reduced the risk of locoregional and distant recurrence among breast cancer patients with tumors measuring less than 5 cm and... (Source: OncologySTAT Latest News)...
POSTED 07/01/2009 at 09:58 AM --
|
BioSante Pharmaceuticals Comments On Study Showing No Increased Risk Of Breast Cancer In Women Using Testosterone For Low Libido
BioSante Pharmaceuticals, Inc. (Source: Health News from Medical News Today)...
POSTED 07/01/2009 at 05:00 AM --
|
ABRAXANE Approved For Advanced Breast Cancer Patient Treatment In Quebec
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated biotechnology company, announced the listing of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg in Quebec for the treatment of metastatic breast cancer with a recommendation from the Quebec Conseil du Médicament and approval from the Quebec Ministry of Health. (Source: Health News from Medical News Today)...
POSTED 07/01/2009 at 05:00 AM --
|
Metabolic Factors May Play A Role In Risk For Breast Cancer
Physiological changes associated with the metabolic syndrome may play a role in the risk of postmenopausal breast cancer, according to study results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. (Source: Health News from Medical News Today)...
POSTED 07/01/2009 at 04:00 AM --
|
XCounter Announces Positive Results Following Independent Clinical Evaluation Of XC Mammo -3T Prototype
XCounter AB (publ) (AIM:XCT), a technology leader in the development of tomosynthesis-based 3D medical imaging, announced positive initial results from the first clinical evaluation of its innovative breast screening device XC Mammo - 3T. The device is the world's first dedicated 3D digital mammography system for the detection of breast cancer, the most common form of cancer found in women. (Source: Health News from Medical News Today)...
POSTED 07/01/2009 at 02:00 AM --
|
Cancer: An Ounce of Prevention
Exercise and eat away your risk for breast cancer. (Source: Psychology Today)...
POSTED 06/30/2009 at 11:00 PM --
|
BRCA1 Gene
BRCA1 is a gene that, when healthy, prevents breast tumors from forming. It is associated with hereditary breast cancer. (Source: About.com Breast Cancer)...
POSTED 06/30/2009 at 06:00 PM --
|
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
A controversy has arisen over the past several years about the true origin of the human MDA-MB-435 cell line. Originally described as a human breast cancer cell line, subsequent expression array studies instead suggested a gene expression profile consistent with a melanoma origin. Subsequent karyotype and comparative genomic hybridization studies supported the idea that current stocks of both MDA-MB-435 cells and M14 melanoma cells must be identical cell lines, and the conclusion was drawn that both cell lines were in fact M14 melanoma cells. However, an alternate conclusion based on these data is that both cell lines are indeed identical, but are in fact MDA-MB-435 breast cancer cells. There is evidence that many cell lines can display "lineage infidelity" and that assignment to tissue ty......
POSTED 06/30/2009 at 06:00 PM --
|
Phosphoglucose Isomerase/Autocrine Motility Factor Mediates Epithelial and Mesenchymal Phenotype Conversions in Breast Cancer
Phosphoglucose isomerase/autocrine motility factor (PGI/AMF) is a housekeeping gene product/cytokine that catalyzes a step in glycolysis and gluconeogenesis, and acts as a multifunctional cytokine associated with aggressive tumors. PGI/AMF has been correlated significantly with breast cancer progression and poor prognosis in breast cancer. We show here that ectopic expression of PGI/AMF induced epithelial-to-mesenchymal transition (EMT) in MCF10A normal human breast epithelial cells, and inhibition of PGI/AMF expression triggered mesenchymal-to-epithelial transition (MET) in aggressive mesenchymal-type human breast cancer MDA-MB-231 cells. EMT in MCF10A cells was shown by morphologic changes and loss of E-cadherin/β-catenin–mediated cell-cell adhesion, which is concomitant with ......
POSTED 06/30/2009 at 06:00 PM --
|
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy. Its effect on relapse and survival is uncertain. Its prognostic value for survival was analyzed in three databases of previously reported prospective multicenter studies: (a) FEC chemotherapy in metastatic breast carcinoma; (b) CYVADIC in advanced soft tissue sarcoma (European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group 62791); and (c) prospective, consecutive phase III studies of aggressive diffuse large-cell non–Hodgkin's lymphomas conducted at Centre Léon Bérard between 1987 and 1993. Univariate and multivariate analyses of prognostic factors for survival were performed. The incidence of lymphopenia of <1,000/µL before treatme......
POSTED 06/30/2009 at 06:00 PM --
|
Subcellular Localization of Cyclic AMP-Responsive Element Binding Protein-Regulated Transcription Coactivator 2 Provides a Link between Obesity and Breast Cancer in Postmenopausal Women
In conclusion, the regulation of aromatase by CRTC2, in response to the altered hormonal milieu associated with menopause and obesity, provides a critical link between obesity and breast cancer. [Cancer Res 2009;69(13):5392–9] (Source: Cancer Research)...
POSTED 06/30/2009 at 06:00 PM --
|
Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell Migration In vitro and Causes Tumor Regression In vivo
Signal transduction modifiers that modulate the lysophosphatidic acid (LPA) pathway have potential as anticancer agents. Herein, we describe metabolically stabilized LPA analogues that reduce cell migration and invasion and cause regression of orthotopic breast tumors in vivo. Two diastereoisomeric -bromophosphonates (BrP-LPA) were synthesized, and the pharmacology was determined for five LPA G protein–coupled receptors (GPCRs). The syn and anti diastereomers of BrP-LPA are pan-LPA GPCR antagonists and are also nanomolar inhibitors of the lysophospholipase D activity of autotaxin, the dominant biosynthetic source of LPA. Computational models correctly predicted the diastereoselectivity of antagonism for three GPCR isoforms. The anti isomer of BrP-LPA was more effective than syn isome......
POSTED 06/30/2009 at 06:00 PM --
|
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
Conclusions:
Although the Wnt antagonist genes WIF1 and DKK3 show a very similar frequency of promoter methylation in human breast cancer, only DKK3 methylation proves as a novel prognostic marker potentially useful in the clinical management of this disease. (Source: BMC Cancer)...
POSTED 06/30/2009 at 06:00 PM --
|
Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
CONCLUSION: Expression of CK5/6 and HER-1 is frequent in ER-negative breast cancers, in triple negative and in non-triple negative tumours. In a minority of cases, HER-1 overexpression may be caused by HER-1 gene amplification. Further studies are needed to investigate whether such cases might benefit from anti-HER-1 therapy.
PMID: 19561231 [PubMed - in process] (Source: Cancer Control)...
POSTED 06/30/2009 at 06:00 PM --
|
Identification Of Osteopontin-Dependent Signaling Pathways In Human Breast Cancer
Conclusion:
We conclude that secreted OPN regulates multiple signaling pathways critical for local tumor progression. (Source: BMC Research Notes)...
POSTED 06/30/2009 at 06:00 PM --
|
Do high-volume hospitals and surgeons provide better care in urologic oncology?
Abstract: Studies focusing primarily on hospital or surgical volume as a surrogate for surgical experience have found substantial variations in outcomes. Increasing surgical experience has been shown to improve outcomes after multiple procedures, including esophagectomy, pancreatectomy, and primary surgery for colon and breast cancer. More recently, evidence has been presented that surgical volume/experience affects quality of life and cancer control outcomes after urologic oncology procedures. Although most of these data pertain to radical prostatectomy, similar conclusions have been reached for radical cystectomy, retroperitoneal lymph node dissection, and management of renal cell carcinoma. This review highlights data indicating that high-volume surgeons and hospitals provide better car......
POSTED 06/30/2009 at 06:00 PM --
|
Breast cancer treatments impact work status
NEW YORK (Reuters Health) - Among working women with newly diagnosed breast cancer, those treated with chemotherapy appear more likely to experience a major change in work status, study findings suggest. (Source: Reuters: Health)...
POSTED 06/30/2009 at 03:28 PM --
|
